Autopsy report · NCT00155714

Efficacy of Type-5 Phosphodiesterase Inhibitors in Primary and Secondary Pulmonary Hypertension

Cause of deathOther Automatic label, confidence 0.5, unverified. How labels are made.

“We can't obtained the test drug (Vadenafil) from Bayer. They decided not to carry out this trail in Taiwan. Therefore this trail has never been started.”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Na
Sponsor: National Taiwan University Hospital
Sponsor type: University, hospital or other
Conditions: Primary and Secondary Pulmonary Hypertension
Interventions: type-5 phosphodiesterase Inhibitor (Sildenafil)
Participants: 20 (planned, not actual)
Sites: 1
Countries: Taiwan

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.